Pyrexar Medical Heats up Chicago at the RSNA

Salt Lake City, USA, 12/12/2015 / SubmitMyPR /

Pyrexar Medical, leaders in thermal therapy systems, exhibited at the Radiological Society of North America (RSNA) Annual Meeting held last week in Chicago’s McCormick Place.

Pyrexar showcased their line of superficial, interstitial and deep regional hyperthermia systems for the treatment of cancer. Touted at the world’s largest medical device conference, the RSNA attracted radiology professionals from around the world.

Distributors from all over the world use the RSNA to learn about new technologies and to add devices to their product offering.  “I have been attending RSNA for over thirty years”, says Mark Falkowski, CEO at Pyrexar Medical.  “The relationships and introductions you make at the show are a very important part of our total marketing and sales strategy.” This year was no different as distributors from over 30 countries were in the Pyrexar booth vying for the hyperthermia line.

In a related conference event, Mark Dewhirst, DVM, PhD from Duke University Medical Center presented "Lessons Learned from XRT/Hyperthermia”.   In his presentation Dr. Dewhirst explained how hyperthermia compliments the ability of radiotherapy to kill cancer cells and reviewed the more than a dozen positive phase III cancer trials where hyperthermia was used in conjunction with radiotherapy.  He also provided new insights on how hyperthermia affects the process of DNA damage repair.

This was Pyrexar Medical’s first year at RSNA and space has already been reserved for next year’s conference in Boston.

ABOUT PYREXAR MEDICAL:
Pyrexar Medical is a pioneer and worldwide market leader in the development and manufacture of innovative and highly effective thermal therapy/hyperthermia treatment systems with established distribution and support networks around the world. PYREXAR HyperThermia (PYREXAR HT) treatments, proven in multiple clinical trials over the last 30 years, increase the effective dose of ionizing radiation in solid tumors up to 3X without increasing toxicity to healthy tissue.  For more information visit our website www.pyrexar.com